search
Back to results

Glutamine Supplementation and Short-term Mortality in Covid-19

Primary Purpose

Covid19

Status
Completed
Phase
Phase 3
Locations
Egypt
Study Type
Interventional
Intervention
Standard enteral nutrition
Glutamine
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Covid19

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of covid-19 diseased patients admitted to the ICU with enteral nutrition.

Exclusion Criteria:

  • Renal failure (creatinine >180 mmol/l)
  • Hepatic failure (bilirubin >40 mmol/l, alanine aminotransferase >100 U/l and aspartate aminotransferase >100 U/l)
  • Severe neutropenia (<500 cells/mm3)
  • Patients receiving cytotoxic, radiation and/or steroid therapy
  • Hemodynamic instability

Sites / Locations

  • Omar Soliman

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Group EN (standard enteral nutrition)

Group GN (glutamine supplemented enteral nutrition)

Arm Description

Patients receive standard enteral nutrition according to ICU nutrition protocol during 7days from admission

Patients receive intravenous glutamine supplementation to enteral nutrition in a dose of glutamine of 0.4 g/kg/day during 7 days from admission.

Outcomes

Primary Outcome Measures

ICU mortality
Short-term ICU mortality for patients admitted in our ICU & signed for study drugs, who will expire during the study

Secondary Outcome Measures

Neutrophil/lymphocyte ratio (NLR)
Assessing NLR at day zero & day 7 to monitor inflammatory response
D- dimer level
Assessing D-dimer level at day zero &day 7 to monitor coagulability status
ICU stay
Period of patients admission in ICU within duration of study

Full Information

First Posted
May 30, 2021
Last Updated
November 4, 2021
Sponsor
Assiut University
search

1. Study Identification

Unique Protocol Identification Number
NCT04909905
Brief Title
Glutamine Supplementation and Short-term Mortality in Covid-19
Official Title
The Impact of Glutamine Supplementation Upon the Short-term Mortality of COVID-19 Diseased Patients Admitted in ICU: A Double Blind Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
May 30, 2021 (Actual)
Primary Completion Date
October 25, 2021 (Actual)
Study Completion Date
October 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to investigate the effect of parenteral L-Glutamine supplementation added to enteral nutrition on short-term ICU mortality (7 days) in Covid-19 diseased patients.
Detailed Description
A written informed consent will be taken from the patients or their relatives. Patients with diagnosis of covid-19 with enteral nutrition will be enrolled. Patients will be randomly assigned to receive either standard enteral nutrition (Group EN) or intravenous glutamine supplementation to enteral nutrition (group GN) in a dose of glutamine of 0.4 g/kg/day during ICU stay.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid19

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group EN (standard enteral nutrition)
Arm Type
Experimental
Arm Description
Patients receive standard enteral nutrition according to ICU nutrition protocol during 7days from admission
Arm Title
Group GN (glutamine supplemented enteral nutrition)
Arm Type
Experimental
Arm Description
Patients receive intravenous glutamine supplementation to enteral nutrition in a dose of glutamine of 0.4 g/kg/day during 7 days from admission.
Intervention Type
Dietary Supplement
Intervention Name(s)
Standard enteral nutrition
Intervention Description
Standard enteral nutrition according to ICU nutrition protocol for 7 days
Intervention Type
Combination Product
Intervention Name(s)
Glutamine
Other Intervention Name(s)
Dipeptiven
Intervention Description
Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days
Primary Outcome Measure Information:
Title
ICU mortality
Description
Short-term ICU mortality for patients admitted in our ICU & signed for study drugs, who will expire during the study
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Neutrophil/lymphocyte ratio (NLR)
Description
Assessing NLR at day zero & day 7 to monitor inflammatory response
Time Frame
7 days
Title
D- dimer level
Description
Assessing D-dimer level at day zero &day 7 to monitor coagulability status
Time Frame
7 days
Title
ICU stay
Description
Period of patients admission in ICU within duration of study
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of covid-19 diseased patients admitted to the ICU with enteral nutrition. Exclusion Criteria: Renal failure (creatinine >180 mmol/l) Hepatic failure (bilirubin >40 mmol/l, alanine aminotransferase >100 U/l and aspartate aminotransferase >100 U/l) Severe neutropenia (<500 cells/mm3) Patients receiving cytotoxic, radiation and/or steroid therapy Hemodynamic instability
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Omar Soliman, MD
Organizational Affiliation
Omar makram
Official's Role
Principal Investigator
Facility Information:
Facility Name
Omar Soliman
City
Assiut
State/Province
Assuit
ZIP/Postal Code
Assuit universi
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
32341077
Citation
Mehta S. Nutritional status and COVID-19: an opportunity for lasting change? Clin Med (Lond). 2020 Apr 27;20(3):270-3. doi: 10.7861/clinmed.2020-0187. Online ahead of print.
Results Reference
background

Learn more about this trial

Glutamine Supplementation and Short-term Mortality in Covid-19

We'll reach out to this number within 24 hrs